Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects
ConclusionINTP5 showed PK/PD equivalence with pegfilgrastim-ref following a single dose, no clinically meaningful difference in the immune response following multiple doses, and a comparable safety profile. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 24, 2020 Category: Drugs & Pharmacology Source Type: research

Acknowledgement to Referees
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 18, 2020 Category: Drugs & Pharmacology Source Type: research

Preferential Antiseizure Medications in Pediatric Patients with Convulsive Status Epilepticus: A Systematic Review and Network Meta-Analysis
ConclusionsThis study demonstrated the hierarchy of competing interventions. Midazolam could be a better option for first-line treatment. Phenobarbital, levetiracetam, and valproate had their respective superiority in the second-line intervention. This study may provide useful information for clinical decision making under different circumstances. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 4, 2020 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
ConclusionOur study found that, at current prices, lenvatinib is a cost-effective treatment option compared with sorafenib  for the first-line treatment of patients with advanced HCC. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 2, 2020 Category: Drugs & Pharmacology Source Type: research

Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study
AbstractBackground and ObjectivesGlobalagliatin, a glucokinase activator, plays a vital role in glucose homeostasis. The aim of this study was to assess the safety, pharmacokinetics, and pharmacodynamics of globalagliatin in Chinese patients with type 2 diabetes.MethodsIn this dose-titration study, 24 patients were randomized (3:1 ratio) to receive globalagliatin or placebo. The 28-day titration was divided into two stages, each comprising 12 subjects. In stage I (low-dose), globalagliatin or placebo was administered at ascending doses of 20, 40, 80, and 120  mg once daily, increased at weekly intervals. As the treatm...
Source: Clinical Drug Investigation - October 30, 2020 Category: Drugs & Pharmacology Source Type: research

Data Mining for Adverse Events of Tumor Necrosis Factor-Alpha Inhibitors in Pediatric Patients: Tree-Based Scan Statistic Analyses of Danish Nationwide Health Data
ConclusionsNo signals of previously unknown adverse events of TNF- α inhibitors in pediatric patients were detected. The study showed that real-world data and newly developed methods for adverse events data mining can play a particularly important role in pediatrics where pre-approval drug safety data are scarce. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 26, 2020 Category: Drugs & Pharmacology Source Type: research

Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
ConclusionsThe observations suggested that treatment with pembrolizumab monotherapy or pembrolizumab plus chemotherapy is a cost-effective strategy for patients with R/M HNSCC in the USA. However, the conclusion is the opposite for China: the EXTREME regimen is still a cost-effective choice. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 23, 2020 Category: Drugs & Pharmacology Source Type: research

Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
ConclusionIn this small case series, the use of DOACs in CML patients seemed feasible. Additional data on long-term outcomes including a larger cohort of CML patients treated with DOACs are, however, needed. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 22, 2020 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon  α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus
ConclusionPharmacokinetic and pharmacodynamic analyses of the data from this study demonstrated that there was biphasic disposition in both healthy subjects and subjects with SLE, CL was faster in subjects with SLE, and increases in total IFN α/ω levels were observed in both healthy subjects and subjects with SLE after treatment with JNJ-55920839, thus further development is supported.The study is registered at ClinicalTrials.gov NCT02609789. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 21, 2020 Category: Drugs & Pharmacology Source Type: research

Treatment of Major Depressive Disorder in Japanese Patients with Cancer: A Matched Cohort Study Using Employer-Based Health Insurance Claims Data
AbstractBackground and ObjectivePatients with cancer are at high risk of major depressive disorder (MDD), but little is known about their MDD treatment. We investigated the use of antidepressants and other drugs for MDD after cancer diagnosis, and patient characteristics associated with their use.MethodsAdults with a new cancer diagnosis were matched to cancer-free patients using a Japanese employee health insurance database (JMDC); this exploratory analysis included only cohort patients diagnosed with MDD between 6 months before and 12 months after the cancer diagnosis index month. Initial prescription frequencies of anti...
Source: Clinical Drug Investigation - October 18, 2020 Category: Drugs & Pharmacology Source Type: research

Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
AbstractDue to the risks involved in not achieving desired health outcomes for the dollar spent on drugs, healthcare decision makers, including payers, providers, drug manufacturers, and patients, need a mechanism to share this financial risk among the involved parties. Performance-based risk-sharing arrangements (PBRSAs) are agreements that can potentially reduce the ‘drug lag’ in which patients wait for an unknown amount of time until a particular drug is covered under their health plan. In addition, PBRSAs can mitigate the risk of investing heavily in drugs that are ineffective or do not deliver good value o...
Source: Clinical Drug Investigation - October 9, 2020 Category: Drugs & Pharmacology Source Type: research

Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice
AbstractHormonal contraceptives are used worldwide by more than 100 million women. Some studies have been published about the possible appearance of depressive symptoms when using hormonal contraceptives, but this link is still a matter of debate. The purpose of this review is to provide an update of the literature on this issue, and to investigate the possible explanations of this problem based on animal and human studies. The main pathway responsible for menstrual cycle-related mood changes is the γ-aminobutyric acid pathway, which is sensitive to changes in the levels of progesterone and of its metabolites, the ne...
Source: Clinical Drug Investigation - September 26, 2020 Category: Drugs & Pharmacology Source Type: research

Treatment and Healthcare Cost Among Patients with Hip or Knee Osteoarthritis: A Cross-sectional Study Using a Real-world Claims Database in Japan Between 2013 and 2019
ConclusionsAlthough a considerable change in total healthcare cost was not observed in our study, the contents of medical treatment and cost breakdown were greatly altered due to the treatment and cost for OA itself, and the treatment and cost for comorbidities. Similar studies to investigate such a trend may help predict necessary resources and social needs. Thus, further investigation utilizing other databases is needed. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 22, 2020 Category: Drugs & Pharmacology Source Type: research

Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations
ConclusionThis study suggests that it is cost effective to screen for LOF mutations in the CYP2C19 gene in ischemic stroke populations, with ticagrelor as a substitute for clopidogrel in those with LOF mutations. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 20, 2020 Category: Drugs & Pharmacology Source Type: research

Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 19, 2020 Category: Drugs & Pharmacology Source Type: research

Community-Acquired Bacterial Pneumonia —Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
AbstractCommunity-acquired pneumonia (CAP) is a major cause of morbidity and mortality both in the USA and globally. As the burden of CAP continues to increase due to several factors, the advances in its diagnosis, prevention, and treatment have taken on even greater interest and importance. The majority of CAP patients are treated empirically, and selection of appropriate antibiotic treatment is increasingly difficult because the epidemiology of CAP is changing, in part due to antimicrobial resistance, and the causative CAP pathogens differ between countries and regions. There is also an increasing prevalence of chronic c...
Source: Clinical Drug Investigation - September 4, 2020 Category: Drugs & Pharmacology Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention
ConclusionsOur real-life data study suggests that secondary stroke prevention with DOACs is as effective and safe as primary prevention, both in standard and reduced doses, in a typical group of patients who are older than patients included in RCTs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 3, 2020 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5  mg Formulation, in Opioid-Naïve Patients with Cancer Pain
ConclusionA low-dose fentanyl citrate patch was effective in the management of cancer pain in opioid-na ïve patients and was well tolerated.Study RegistrationJPRN-JapicCTI-173717. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 3, 2020 Category: Drugs & Pharmacology Source Type: research

New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 29, 2020 Category: Drugs & Pharmacology Source Type: research

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug –Drug Interactions
AbstractDoravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) infection. The recommended dose is 100  mg once daily. This review summarizes the pharmacokinetics of doravirine, the influence of intrinsic factors, and its drug–drug interaction (DDI) profile. Following oral administration, doravirine is rapidly absorbed (median time to maximum plasma concentration, 1–4 h) and undergoes cytochrom e P450 (CYP)3A-mediated oxidative metabolism. Steady-state geometric means for AUC0 –24,C24, a...
Source: Clinical Drug Investigation - August 19, 2020 Category: Drugs & Pharmacology Source Type: research

Use of Azithromycin in COVID-19: A Cautionary Tale
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 19, 2020 Category: Drugs & Pharmacology Source Type: research

Drug –Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
ConclusionsDOACs and DAAs are under-investigated for DDI risk. Real-world studies are needed to assess the clinical relevance of the pharmacokinetic interactions with dabigatran and describe the actual spectrum of possible DDIs between DAAs and other DOACs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 17, 2020 Category: Drugs & Pharmacology Source Type: research

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database
ConclusionsThis study suggests that there is no association between exposure to golimumab and an increased risk of prespecified outcomes. Increased depression risk in the as-treated analysis was not replicated in other analyses and may be associated with residual imbalance in baseline history or severity of depression. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 9, 2020 Category: Drugs & Pharmacology Source Type: research

Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
AbstractDuring the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more attention should be paid to the balance of risks and benefits associated with proton pump inhibitors for the following reasons. One of the main functions of gastric juice is to inactivate swallowed microorganisms, thereby inhibiting infectious agents from reaching the intestine. Studies have documented that proton pump inhibitors are a risk factor for rotavirus, influenza virus, norovirus, and Middle East respiratory syndrome coronavirus infections, and are associated with an increased risk of acute gastroenteritis dur...
Source: Clinical Drug Investigation - August 9, 2020 Category: Drugs & Pharmacology Source Type: research

Remifentanil Target-Controlled Infusion for Conscious Sedation in Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Case Series
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 6, 2020 Category: Drugs & Pharmacology Source Type: research

Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France
AbstractBackground and ObjectivesNon-interventional studies are a valuable source of evidence that is complementary to traditional randomised, blinded and controlled clinical trials, for evaluating antidepressants in a real-world setting. The aim of the present  study was to document the use of agomelatine in current medical practice and evaluate its effectiveness and safety in outpatients prescribed agomelatine to treat their current depressive episode.MethodsThis 12-month observational French study included patients initiating agomelatine treatment. The intensity and severity of depression were assessed using t...
Source: Clinical Drug Investigation - July 28, 2020 Category: Drugs & Pharmacology Source Type: research

Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus
AbstractSodium-glucose cotransporter inhibitors are a new class of oral antihyperglycemic drugs that have been approved for the treatment of patients with type 2 diabetes mellitus. Sodium-glucose cotransporter inhibitors reduce glucose reabsorption in the kidneys, which lowers blood glucose. In addition, they offer significant cardiovascular benefits and renal protection. Multiple phase III trials of sodium-glucose cotransporter inhibitors in patients with type 1 diabetes have been completed. The European Medicines Agency approved dapagliflozin as an adjuvant therapy to insulin for patients with type 1 diabetes who have po...
Source: Clinical Drug Investigation - July 27, 2020 Category: Drugs & Pharmacology Source Type: research

Comprehensive Pulmonary Safety Review of Inhaled Technosphere ® Insulin in Patients with Diabetes Mellitus
ConclusionsPulmonary safety assessment of the TI inhalation system did not identify any safety issues in individuals with either T1DM or T2DM. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 26, 2020 Category: Drugs & Pharmacology Source Type: research

Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety
AbstractCefiderocol (Fetroja®) is a siderophore cephalosporin and has demonstrated potent activity against extended-spectrum beta-lactamases producingEnterobacteriaceae, carbapenem-resistantEnterobacteriaceae, and nonfermenting Gram-negative bacilli, includingPseudomonas aeruginosa,Stenotrophomonas maltophilia, andAcinetobacter baumannii, Burkholderia cepacia, andKlebsiella pneumoniae. However, cefiderocol has limited activity against Gram-positive bacteria and anaerobes likeBacterodies fragilis. In the APEKS-cUTI study, 183 (73%) of 252 patients in the cefiderocol group versus 65 (55%) of 119 patients in the imipenem-...
Source: Clinical Drug Investigation - July 21, 2020 Category: Drugs & Pharmacology Source Type: research

Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database
ConclusionsOur study shows increased reporting of facial paralysis following influenza vaccination as compared with other vaccines. Considering the inherent limitations of the VAERS database analysis, and the fact that disproportionality measures only indicate the presence of a signal, our study findings need to be explored in well-designed prospective pharmacoepidemiologic studies. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 20, 2020 Category: Drugs & Pharmacology Source Type: research

High Doses of Δ 9 -Tetrahydrocannabinol Might Impair Irinotecan Chemotherapy: A Review of Potentially Harmful Interactions
AbstractThis review proposes the hypothesis that the effectiveness of irinotecan chemotherapy might be impaired by high doses of concomitantly administered Δ9-tetrahydrocannabinol (THC). The most important features shared by irinotecan and THC, which might represent sources of potentially harmful interactions are: first-pass hepatic metabolism mediated by cytochrome P450 (CYP) enzyme CYP3A4; glucuronidation mediated by uridine diphosphate glycosyltransferase (UGT) enzymes, isoforms 1A1 and 1A9; transport of parent compounds and their metabolites via canalicular ATP-binding cassette (ABC) transporters ABCB1 and ABCG2;...
Source: Clinical Drug Investigation - July 20, 2020 Category: Drugs & Pharmacology Source Type: research

Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review
AbstractIdiosyncratic drug-induced neutropenia (DIN) is a rare, potentially fatal adverse reaction. A literature search was performed on Pubmed and Embase, targeting articles indicating neutropenia as a complication during the treatment of non-neoplastic dermatological disorders. In 66 identified articles, the common incriminated drugs included conventional oral immunomodulators, topical cytotoxic agents, antibacterials, antifungals, biologics and targeted synthetic disease-modifying antirheumatic drugs, non-steroidal anti-inflammatory drugs, and retinoids, with dapsone being reported most often. The duration of drug expos...
Source: Clinical Drug Investigation - July 20, 2020 Category: Drugs & Pharmacology Source Type: research

Efficacy of Statin/Ezetimibe for Secondary Prevention  of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
This study aimed to summarize study results regarding the effect of statin/ezetimibe combination therapy on lipid parameters and highly sensitive C-reactive protein (HsCRP) biomarkers in ASCVD patients from Asian countries.MethodsWe searched the PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar databases for relevant papers published from 2008 to June 2020. We included randomized controlled trials (RCTs) that (1) were conducted in ASCVD patients in Asian countries; (2) examined the effects of statin/ezetimibe combination therapies compared with a control group; and (3) reported sufficient data on lipid parameters ...
Source: Clinical Drug Investigation - July 14, 2020 Category: Drugs & Pharmacology Source Type: research

P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
AbstractBackground and ObjectivesDual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) reduces the incidence of thrombotic events but increases the risk of bleeding, which is associated with a substantial and durable risk of death and could offset the benefits of a reduction in thrombotic events. P2Y12 inhibitor monotherapy after short-term DAPT could be an option to reduce the risk of bleeding. We carried out a meta-analysis comparing P2Y12 inhibitor monotherapy after short-term DAPT with standard-term DAPT in patients undergoing PCI.MethodsWe searched the PubMed and EMBASE databases through 11 A...
Source: Clinical Drug Investigation - July 12, 2020 Category: Drugs & Pharmacology Source Type: research

Effects of Tranexamic Acid on Hemoptysis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionTXA use was observed to reduce bleeding volume, further intervention risk, and length of hospital stay in patients with hemoptysis; however, our results may have low statistical power because of limited sample size. Additional large-scale RCTs are thus warranted to confirm the effectiveness and safety of TXA use. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 12, 2020 Category: Drugs & Pharmacology Source Type: research

Tocilizumab, Adipokines and Severe Complications of COVID-19
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 12, 2020 Category: Drugs & Pharmacology Source Type: research

Authors ’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 12, 2020 Category: Drugs & Pharmacology Source Type: research

The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model
ConclusionThe results of the budget impact analyses provide conservative estimates of the impact of adding delafloxacin to outpatient formularies in substitution of moxifloxacin. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 9, 2020 Category: Drugs & Pharmacology Source Type: research

Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database
ConclusionWe detected new AE signals of paliperidone that were not listed on the drug labels of six countries, and many that were related to psychotic symptoms, metabolic problems, and endocrine disorders. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 8, 2020 Category: Drugs & Pharmacology Source Type: research

Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
ConclusionsThe use of lurasidone (74  mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 8, 2020 Category: Drugs & Pharmacology Source Type: research

Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study
ConclusionsThis study suggests that there is no particular concern about adverse drug reactions or the efficacy of topiroxostat for hyperuricemic patients with or without gout in a post-marketing setting in Japan. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 2, 2020 Category: Drugs & Pharmacology Source Type: research

Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements
ConclusionsThis small, exploratory study found similar rates of thromboembolic complications and major bleeding events in patients who received a DOAC versus warfarin after a recent bioprosthetic AVR or MVR. This study was limited by its retrospective nature and its sample size. Larger, randomized controlled trials are needed to further determine the efficacy and safety of DOACs in this patient population. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 29, 2020 Category: Drugs & Pharmacology Source Type: research

Investigation of Potential Drug –Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis
ConclusionsPharmacokinetic results showed no significant interactions between peficitinib and methotrexate.ClinicalTrials.gov IdentifierNCT01754805. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 25, 2020 Category: Drugs & Pharmacology Source Type: research

Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain
ConclusionUsing DI as a surrogate for OIRD indicates improved respiratory safety with oliceridine versus morphine that merits further investigation. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 23, 2020 Category: Drugs & Pharmacology Source Type: research

Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
AbstractPolycystic ovary syndrome is a complex and heterogenous disorder involving multiple organ systems and different molecular pathways. It is tightly associated with obesity and especially abdominal obesity. As body weight reduction is the main modifiable risk factor for polycystic ovary syndrome, therapeutic approaches in overweight or obese women with polycystic ovary syndrome have been developed. Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus. The majority of curr...
Source: Clinical Drug Investigation - June 23, 2020 Category: Drugs & Pharmacology Source Type: research

RETRACTED ARTICLE: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 23, 2020 Category: Drugs & Pharmacology Source Type: research

Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review
ConclusionThe results of this systematic review showed that using rivaroxaban in patients undergoing total knee or hip replacement reduced costs and increased quality of life. However, since most of the studies had been conducted in developed countries, it is not possible to generalize the results to developing countries. Nonetheless, given that rivaroxaban is administered orally and does not require continuous monitoring, it will be less costly for patients and health systems and is more appropriate to administer it as a thromboprophylactic drug following total knee or hip replacement surgery. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 22, 2020 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive
ConclusionsCoadministration of vixotrigine and an oral contraceptive containing ethinyl estradiol and levonorgestrel had no clinically relevant effect on exposure of all three compounds.Trial RegistrationClinicalTrials.gov registration number: NCT03324685 (registered 25 October, 2017). (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 19, 2020 Category: Drugs & Pharmacology Source Type: research

Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events
ConclusionPatients with a short-term, drug-induced decrease in HDL-C had a moderately increased long-term risk of CV events compared with those with constant HDL-C levels.Trial Registration Number207595 (GlaxoSmithKline Trial registry;https://www.gsk-studyregister.com/). (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 17, 2020 Category: Drugs & Pharmacology Source Type: research

Azithromycin for COVID-19: More Than Just an Antimicrobial?
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 11, 2020 Category: Drugs & Pharmacology Source Type: research